The Predictive Value of Proteome Profiling for Brain Metastasis in Limited-Stage Small-Cell Lung Cancer

NCT06483919 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 228

Last updated 2024-07-03

No results posted yet for this study

Summary

This study aims to evaluate the predictive value of proteome profiling for brain metastasis in limited-stage small-cell lung cancer

Conditions

  • Small-cell Lung Cancer

Sponsors & Collaborators

  • Jinming Yu

    lead OTHER

Principal Investigators

  • Xiangjiao Meng, PhD · Shandong Cancer Hospital and Institute

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-01
Primary Completion
2025-01-30
Completion
2025-01-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06483919 on ClinicalTrials.gov